Related Experiment Video
Updated: Jul 14, 2026
Surgical Technique for the Implantation of Tissue Engineered Vascular Grafts and Subsequent In Vivo Monitoring
Published on: April 3, 2015
Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency
Jinkyu Park1, Muhammad Riaz2, Lingfeng Qin3
1Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Department of Physiology, College of Medicine, Hallym University, Hallymdaehak-gil, Chuncheon-si 24252, Gangwon-Do, South Korea.
Engineered vascular grafts using stem cells show promise for congenital heart defects. These new grafts prevent clotting and integrate well, offering a potential new therapy for patients.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Cardiovascular Research
Background:
- Tissue-engineered vascular conduits (TEVCs) show potential for treating single-ventricle congenital heart defects (SVCHDs).
- Clinical use of TEVCs is limited by graft stenosis observed in previous trials.
Purpose of the Study:
- To develop endothelialized TEVCs using human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) to improve graft function and reduce stenosis.
- To evaluate the antithrombotic properties and host integration of these novel TEVCs in vivo.
Main Methods:
- Decellularized human umbilical arteries were coated with hiPSC-derived ECs.
- Grafts underwent shear stress training in flow bioreactors.
- Implantation as interposition inferior vena cava grafts in nude rats was performed.
Main Results:
- Endothelialized TEVCs demonstrated immediate antithrombotic function.
- Accelerated host EC recruitment and graft patency were observed post-implantation.
- No thrombus formation occurred, and complete host EC replacement was achieved.
Conclusions:
- Developed endothelialized TEVCs offer immediate antithrombotic benefits and promote host integration.
- These fully biologic TEVCs represent a promising innovative therapy for SVCHDs.
- The findings lay the groundwork for future clinical applications of hiPSC-derived EC-based vascular grafts.
